Joshua Chaim

1.9k total citations · 1 hit paper
39 papers, 1.3k citations indexed

About

Joshua Chaim is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research. According to data from OpenAlex, Joshua Chaim has authored 39 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 15 papers in Molecular Biology and 14 papers in Cancer Research. Recurrent topics in Joshua Chaim's work include Renal cell carcinoma treatment (18 papers), Renal and related cancers (14 papers) and Cancer Genomics and Diagnostics (14 papers). Joshua Chaim is often cited by papers focused on Renal cell carcinoma treatment (18 papers), Renal and related cancers (14 papers) and Cancer Genomics and Diagnostics (14 papers). Joshua Chaim collaborates with scholars based in United States, Sweden and Austria. Joshua Chaim's co-authors include Irina Ostrovnaya, Robert J. Motzer, Oğuz Akın, Hedvig Hricak, Paul Russo, A. Ari Hakimi, James J. Hsieh, Maria I. Carlo, Gopa Iyer and Christoph Karlo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Joshua Chaim

35 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

2018 374 citations Min Yuen Teo, Kenneth Seier et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua Chaim United States	14	732	458	408	311	287	39	1.3k
Frank Priou France	15	563 0.8×	621 1.4×	250 0.6×	140 0.5×	246 0.9×	63	1.1k
Jana Barinoff Germany	18	269 0.4×	593 1.3×	159 0.4×	164 0.5×	333 1.2×	49	976
Gerhard Gebauer Germany	23	227 0.3×	854 1.9×	237 0.6×	206 0.7×	517 1.8×	49	1.4k
Tomohiro Haruki Japan	19	613 0.8×	394 0.9×	226 0.6×	143 0.5×	114 0.4×	103	1.1k
Casey W. Williamson United States	13	204 0.3×	376 0.8×	301 0.7×	94 0.3×	184 0.6×	30	926
Regan Fulton United States	17	253 0.3×	664 1.4×	250 0.6×	166 0.5×	371 1.3×	31	1.1k
James Jer‐Min Jian Taiwan	23	475 0.6×	778 1.7×	173 0.4×	304 1.0×	375 1.3×	32	1.9k
Loïc Verlingue France	14	463 0.6×	719 1.6×	223 0.5×	640 2.1×	242 0.8×	51	1.4k
S.H. Goey Netherlands	20	259 0.4×	758 1.7×	272 0.7×	209 0.7×	91 0.3×	31	1.2k
Coraline Dubot France	15	371 0.5×	883 1.9×	232 0.6×	66 0.2×	305 1.1×	64	1.5k

Countries citing papers authored by Joshua Chaim

Since Specialization

Citations

This map shows the geographic impact of Joshua Chaim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua Chaim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua Chaim more than expected).

Fields of papers citing papers by Joshua Chaim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua Chaim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua Chaim. The network helps show where Joshua Chaim may publish in the future.

Co-authorship network of co-authors of Joshua Chaim

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua Chaim. A scholar is included among the top collaborators of Joshua Chaim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua Chaim. Joshua Chaim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kotecha, Ritesh R., Andrea Knežević, Hyung Jun Woo, et al.. (2025). A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. European Urology Oncology. 8(4). 866–870.

Becker, Anton S., Joshua Chaim, & Hebert Alberto Vargas. (2024). Streamlining Radiology Workflows Through the Development and Deployment of Automated Microservices. Journal of Imaging Informatics in Medicine. 37(3). 945–951.

Chaim, Joshua, et al.. (2024). Integrated Automatic Examination Assignment Reduces Radiologist Interruptions: A 2-Year Cohort Study of 232,022 Examinations. Journal of Imaging Informatics in Medicine. 37(1). 25–30. 2 indexed citations

Kotecha, Ritesh R., Andrea Knežević, David H. Aggen, et al.. (2024). A phase I/II study of talazoparib and axitinib in patients with advanced clear cell renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4541–4541.

Kotecha, Ritesh R., Andrea Knežević, Joshua Chaim, et al.. (2023). A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. European Urology Oncology. 7(4). 804–811. 11 indexed citations

Ged, Yasser, Alejandro Sánchez, Sujata Patil, et al.. (2022). Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research. 28(23). 5180–5189. 20 indexed citations

Wibmer, Andreas G., Robert A. Lefkowitz, Yulia Lakhman, et al.. (2022). MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy. Clinical Genitourinary Cancer. 20(4). 319–325. 14 indexed citations

Wibmer, Andreas G., Ines Nikolovski, Joshua Chaim, et al.. (2021). Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes. Radiology. 302(3). 595–602. 18 indexed citations

Becker, Anton S., Joseph P. Erinjeri, Joshua Chaim, et al.. (2021). Automatic Forecasting of Radiology Examination Volume Trends for Optimal Resource Planning and Allocation. Journal of Digital Imaging. 35(1). 1–8. 4 indexed citations

10.

Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255. 27 indexed citations

11.

Sarfaty, Michal, Irina Ostrovnaya, Min Yuen Teo, et al.. (2020). A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract.. Journal of Clinical Oncology. 38(6_suppl). 514–514. 3 indexed citations

12.

Shah, Amishi Y., Ritesh R. Kotecha, Anuradha Chandramohan, et al.. (2019). Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. European Journal of Cancer. 114. 67–75. 87 indexed citations

13.

Shah, Amishi Y., Ritesh R. Kotecha, Anuradha Chandramohan, et al.. (2019). Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.. Journal of Clinical Oncology. 37(7_suppl). 575–575. 8 indexed citations

14.

Hötker, Andreas M., Andreas Meier, Yousef Mazaheri, et al.. (2018). Temporal changes in MRI appearance of the prostate after focal ablation. Abdominal Radiology. 44(1). 272–278. 13 indexed citations

15.

Seddon, Amanda N., Joshua Chaim, Oğuz Akın, et al.. (2018). Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. Leukemia Research. 68. 48–50. 3 indexed citations

16.

Teo, Min Yuen, Kenneth Seier, Irina Ostrovnaya, et al.. (2018). Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology. 36(17). 1685–1694. 374 indexed citations breakdown →

17.

Carlo, Maria I., Joshua Chaim, Sujata Patil, et al.. (2017). Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. Clinical Genitourinary Cancer. 15(6). e987–e994. 37 indexed citations

18.

Lakhman, Yulia, Harini Veeraraghavan, Joshua Chaim, et al.. (2016). Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis. European Radiology. 27(7). 2903–2915. 116 indexed citations

19.

Karlo, Christoph, Pier Luigi Di Paolo, Joshua Chaim, et al.. (2013). Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. Radiology. 270(2). 464–471. 224 indexed citations

20.

Vargas, Hebert Alberto, Joshua Chaim, Robert A. Lefkowitz, et al.. (2012). Renal Cortical Tumors: Use of Multiphasic Contrast-enhanced MR Imaging to Differentiate Benign and Malignant Histologic Subtypes. Radiology. 264(3). 779–788. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact